Question explored with the scientific record
Ok for seniors to take this year’s flu jab
The short version: for a healthy senior, this year's flu shot is a reasonable bet against a real risk, but the evidence here is mostly antibody counts, not fewer hospitalizations or deaths.
The strongest outcome data in this retrieval is about which flu vaccine works better in people 65 and older, not whether to skip it. In a large observational study of US adults 65 and up, the adjuvanted vaccine (Fluad) beat the standard quadrivalent by 18 to 28 percent fewer flu-related medical visits across two seasons [6]. High-dose vaccine beat standard-dose by 13 percent fewer flu-and-pneumonia hospitalizations in VA patients [5]. A Canadian study found flu shots cut flu hospitalizations by about 23 percent overall, but only about 19 percent in people 65 and up, and that senior figure was not statistically significant [5].
| Comparison (adults 65+) | Outcome | Result |
|---|---|---|
| Adjuvanted vs standard | Flu-related medical visits | 18-28% fewer [6] |
| High-dose vs standard | Flu/pneumonia hospitalization | 13% fewer [5] |
| High-dose vs standard | Lab-confirmed flu, hospitalized | 28% fewer, not significant [7] |
| Any flu shot vs none | Flu hospitalization, 65+ | 19%, not significant [5] |
Most of the rest is antibody titers, a lab readout, not proof of fewer illnesses [2][3][4]. The safety data is thin: one Finnish surveillance study of 939 people had only 37 over age 65, and it relied on voluntary self-reporting, which catches almost nothing [1]. There is no long-term safety study here.
My call: for a healthy senior, the shot is worth taking, and the adjuvanted or high-dose version has the best outcome data, but the benefit is modest and the safety evidence is weak. Confidence: moderate.
Sources used 7
-
Enhanced passive safety surveillance of the quadrivalent inactivated split-virion influenza vaccine (IIV4) in Finland during the 2019/20 influenza season
Enhanced passive safety surveillance of IIV4 in Finland in 2019/20 found no clinically significant change in suspected adverse drug reaction frequency or severity, with rates comparable to previous season and SmPC, supporting vaccine safety.
DOI: 10.1186/s12889-021-10378-8 -
Effectiveness, immunogenicity, and safety of influenza vaccines with MF59 adjuvant in healthy people of different age groups
MF59-adjuvanted influenza vaccines improved H1N1 seroconversion/seroprotection and influenza B seroconversion versus non-adjuvanted vaccines, with benefits in healthy adults and older adults.
DOI: 10.1097/md.0000000000019095 -
Greater activation of peripheral T follicular helper cells following high dose influenza vaccine in older adults forecasts seroconversion
This randomized study in adults aged 65 and older shows that high-dose influenza vaccine more robustly activates peripheral T follicular helper (pTfh) cells and plasmablasts than standard-dose vaccine, and that the degree of pTfh activation predicts seroconversion and antibody r…
DOI: 10.1016/j.vaccine.2016.11.059 -
Randomized, Double‐Blind Controlled Phase 3 Trial Comparing the Immunogenicity of High‐Dose and Standard‐Dose Influenza Vaccine in Adults 65 Years of Age and Older
A multicenter, randomized, double-blind Phase 3 trial showed that a high-dose influenza vaccine (60 µg HA per strain) elicited significantly higher humoral immunogenicity (HAI GMTs and seroconversion/seroprotection rates) than the standard-dose vaccine in adults aged 65 and olde…
DOI: 10.1086/599790 -
990. Impact of Influenza Vaccination Setting on Timing of Vaccination in a National Sample of Influenza-Vaccinated Adults
High-dose influenza vaccine was more effective than standard-dose in older VHA patients; IIV4 was similar; Canadian 2016-2017 VE was 23%; H3N2 antibody responses did not differ by vaccine but were lower against cell-propagated virus.
DOI: 10.1093/ofid/ofy210.827 -
Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017–2018 and 2018–2019 Influenza Seasons
In two US influenza seasons, adults aged ≥65 who received MF59-adjuvanted trivalent influenza vaccine had fewer influenza-related medical encounters than those receiving quadrivalent inactivated or high-dose trivalent vaccines.
DOI: 10.1093/cid/ciab152 -
150. Relative Effectiveness of High-Dose and Standard-Dose Influenza Vaccine Against Influenza-Related Hospitalization Among Older Adults—United States, 2015–2017
Among hospitalized adults aged ≥65 years during 2015–2016 and 2016–2017, high-dose influenza vaccine was associated with a non-significant adjusted odds ratio of 0.72 for laboratory-confirmed influenza versus standard-dose vaccine.
DOI: 10.1093/ofid/ofy209.020